186 related articles for article (PubMed ID: 33527351)
1. Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics.
Gerard E; Zohar S; Thai HT; Lorenzato C; Riviere MK; Ursino M
Biometrics; 2022 Mar; 78(1):300-312. PubMed ID: 33527351
[TBL] [Abstract][Full Text] [Related]
2. Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens.
Gerard E; Zohar S; Lorenzato C; Ursino M; Riviere MK
Stat Med; 2021 Oct; 40(23):5096-5114. PubMed ID: 34259343
[TBL] [Abstract][Full Text] [Related]
3. An extended Bayesian semi-mechanistic dose-finding design for phase I oncology trials using pharmacokinetic and pharmacodynamic information.
Yang C; Li Y
Stat Med; 2024 Feb; 43(4):689-705. PubMed ID: 38110304
[TBL] [Abstract][Full Text] [Related]
4. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
Du Y; Yin J; Sargent DJ; Mandrekar SJ
J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose-escalation oncology trials with sequential multiple schedules.
Günhan BK; Weber S; Seroutou A; Friede T
BMC Med Res Methodol; 2021 Apr; 21(1):69. PubMed ID: 33853539
[TBL] [Abstract][Full Text] [Related]
6. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
Gerke O; Siedentop H
Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
[TBL] [Abstract][Full Text] [Related]
7. A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.
Tighiouart M; Cook-Wiens G; Rogatko A
J Biopharm Stat; 2018; 28(3):562-574. PubMed ID: 28858566
[TBL] [Abstract][Full Text] [Related]
8. Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information.
Zhang Y; Kutner M; Chen Z
Biom J; 2021 Oct; 63(7):1476-1492. PubMed ID: 33969525
[TBL] [Abstract][Full Text] [Related]
9. A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes.
Koopmeiners JS; Modiano J
Clin Trials; 2014 Feb; 11(1):38-48. PubMed ID: 24082004
[TBL] [Abstract][Full Text] [Related]
10. Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control.
Tighiouart M; Piantadosi S; Rogatko A
Stat Med; 2014 Sep; 33(22):3815-29. PubMed ID: 24825779
[TBL] [Abstract][Full Text] [Related]
11. DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses.
Ursino M; Biard L; Chevret S
Biom J; 2022 Dec; 64(8):1486-1497. PubMed ID: 34729815
[TBL] [Abstract][Full Text] [Related]
12. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
[TBL] [Abstract][Full Text] [Related]
13. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
[TBL] [Abstract][Full Text] [Related]
14. Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies.
James GD; Symeonides S; Marshall J; Young J; Clack G
BMC Cancer; 2021 Jan; 21(1):7. PubMed ID: 33402104
[TBL] [Abstract][Full Text] [Related]
15. Bayesian dose-finding phase I trial design incorporating pharmacokinetic assessment in the field of oncology.
Takeda K; Komatsu K; Morita S
Pharm Stat; 2018 Nov; 17(6):725-733. PubMed ID: 30066356
[TBL] [Abstract][Full Text] [Related]
16. Designing phase I oncology dose escalation using dose-exposure-toxicity models as a complementary approach to model-based dose-toxicity models.
Pantoja K; Lanke S; Munafo A; Victor A; Habermehl C; Schueler A; Venkatakrishnan K; Girard P; Goteti K
CPT Pharmacometrics Syst Pharmacol; 2022 Oct; 11(10):1371-1381. PubMed ID: 35852048
[TBL] [Abstract][Full Text] [Related]
17. [Introduction of Oncology Dose-Finding Trial Designs].
Takeda K
Gan To Kagaku Ryoho; 2022 Apr; 49(4):365-370. PubMed ID: 35444116
[TBL] [Abstract][Full Text] [Related]
18. dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials.
Toumazi A; Comets E; Alberti C; Friede T; Lentz F; Stallard N; Zohar S; Ursino M
Comput Methods Programs Biomed; 2018 Apr; 157():163-177. PubMed ID: 29477425
[TBL] [Abstract][Full Text] [Related]
19. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies.
Postel-Vinay S; Aspeslagh S; Lanoy E; Robert C; Soria JC; Marabelle A
Ann Oncol; 2016 Feb; 27(2):214-24. PubMed ID: 26578728
[TBL] [Abstract][Full Text] [Related]
20. Competing designs for drug combination in phase I dose-finding clinical trials.
Riviere MK; Dubois F; Zohar S
Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]